EBITDA: Income before interest, taxes, depreciation and amortization.
SpyGlass Pharma, Inc. (SGP) had EBITDA of $-15.09M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-13.82M |
|
-- |
|
-- |
|
$15.41M |
|
$-15.41M |
|
$1.59M |
|
$-13.82M |
|
$-13.82M |
|
$-13.82M |
|
$-13.82M |
|
$-13.82M |
|
$-13.82M |
|
$-15.41M |
|
|
EBITDA |
$-15.09M |
19.93B |
|
19.93B |
|
$-0.69 |
|
$-0.69 |
|
| Balance Sheet Financials | |
$253.36M |
|
$2.75M |
|
$5.02M |
|
$258.39M |
|
$6.67M |
|
-- |
|
$1.61M |
|
$8.27M |
|
$250.11M |
|
$250.11M |
|
$250.11M |
|
33.43M |
|
| Cash Flow Statement Financials | |
$-13.54M |
|
$-1.67M |
|
$157.75M |
|
$96.36M |
|
$238.90M |
|
$142.54M |
|
$1.68M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
38.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.22M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.52% |
|
-5.52% |
|
-5.35% |
|
-5.52% |
|
$7.48 |
|
$-0.00 |
|
$-0.00 |
|